Generalized dystonia occurs in 15 to 25% of persons with cerebral palsy (CP) and responds poorly to medical and surgical treatments.
EREBRAL palsy (CP) occurs in 1.5 to 2.5 of 1000 live births and is associated with movement disorders such as spasticity, athetosis, and dystonia. Dystonia is characterized by sustained muscle contractions, causing twisting and repetitive movements or abnormal postures. 12 It frequently impairs function and may be painful. Dystonia is classified by the patient's age at onset, anatomical distribution, and cause. It may be an idiopathic, independent disorder or secondary to other conditions. Dystonia affects 15 to 25% of persons with CP, in whom it is typically generalized and affects the entire body. 13, 22 Dystonic CP is difficult to treat. Administration of oral medications alone or in conjunction with neurosurgical procedures does not improve dystonia in more than 50% of cases. 20, 21 We initiated this pilot study after we observed one patient whose severe dystonia improved minimally in response to large oral doses of baclofen and was unaffected by intrathecal boluses of baclofen, but who improved dramatically when treated by continuous infusion of intrathecal baclofen via an implanted pump. 3 
Clinical Material and Methods
Twelve consecutive patients with severe generalized dystonic CP were recruited for the study. All had frequent, involuntary, sustained muscle contractions that caused abnormal postures. The dystonia was secondary to perinatal anoxia in 10 of the 12 patients, to perinatal meningitis in one child, and near-drowning in another. Three of the 12 had mild athetosis. No patient was thought to have any significant spasticity, with spasticity being defined as a velocity-dependent increased resistance to passive muscle stretch and "significant" being defined as a score of 3 or greater on the Ashworth scale. 7 Imaging studies were not routinely obtained as part of the study. Patient ages ranged from 4 to 42 years, with a median of 12 years. Two patients were capable of assisting with self-care. In the remainder, the dystonia interfered with care or caused pain. Five patients had received oral medications, such as baclofen and diazepam, without benefit.
The patients were videotaped sitting and supine for 10 to 15 minutes. Afterward, they were sedated and using fluoroscopic guidance, an intrathecal catheter was inserted percutaneously at L3-4 and advanced to the midthoracic level. The external end of the catheter was tunneled subcutaneously around the flank, where it exited and was connected to an external microinfusion pump. During intrathecal baclofen infusion, electrocardiographic response, respiratory rate, and pulse oximetry were continuously monitored, and the patient's level of consciousness was assessed every 4 hours.
Baclofen, 500 g/ml, initially was infused at a rate of 100 g/day and was increased by 50 g every 12 hours until dystonia was obviously decreased in the opinion of the parent or patient, the physical therapist, and the neurosurgeon. At that time, the infusion was stopped, the catheter was withdrawn, and the patient was videotaped again. If patients received 900 g/day for 24 hours with no response or if adverse side effects attributable to baclofen (such as drowsiness or hypotonia) developed, we discontinued the infusion.
The videotapes were reviewed independently by a physical therapist (M.J.B) who was aware of the treatment status and by a pediatric neurologist (M.J.P.) who was blinded to the treatment status of each patient. They graded dystonia on a 5-point scale 1 that had been modified from the Fahn-Marsden dystonia movement scale. 9 An individual grade was assigned for the patient's eyes, mouth, neck, trunk, and each extremity; these grades were summed for an overall score. Wilcoxon signed-rank tests were used to compare dystonia scores before and after intrathecal baclofen infusion. Concordance between the two graders was evaluated with the probability-of-concordance (Kendall's tau) test. The study was approved by the Human Rights Committee of the Children's Hospital of Pittsburgh and by the United States Food and Drug Administration.
In patients whose dystonia responded to the screening infusion, a subcutaneous programmable pump (Synchromed pump; Medtronic, Inc., Minneapolis, Minnesota) and an intrathecal catheter were implanted for long-term continuous intrathecal baclofen infusion.
Results
Generalized dystonia was reduced during the screening infusions in 10 of the 12 patients. Another patient's dystonia improved in his lower extremites, but not in his upper extremities or in his facial or cervical regions. The overall dystonia scores were significantly lower (that is, better) at the end of the infusions than at the start. The rater who was blinded to treatment status noted a mean decrease in overall dystonia scores of 7.3 points (p = 0.003) and the rater who was not blinded to treatment noted a mean decrease of 11 points (p = 0.0002) ( Table 1 ). Scores for the patient's neck, trunk, and all extremities also improved significantly after administration of baclofen (p Ͻ 0.05). There was no significant difference between the two raters in their assessment of overall dystonia scores (p = 0.62) and the probability-of-concordance test result was significant (p = 0.004). Dystonia in most patients did not improve until the baclofen dosage was in the range of 350 to 750 g/day; that is, after 4 to 7 days of infusion.
Meningitis developed in two patients, in one during the infusion trial and in the other 1 day after the infusion catheter was withdrawn. Both patients' dystonia had not responded to the infusion and both were treated successfully with antibiotic therapy. The technique for catheter insertion was altered to minimize cerebrospinal fluid leaks and no infections occurred in the subsequent 10 patients.
Programmable subcutaneous pumps were implanted in eight of the 10 patients who responded to the screening infusions. These patients have been followed for 11 to 24 months (mean 15.6 months) during which time they have received continuous intrathecal baclofen doses of 185 to 625 g/day (mean 441 g/day). Improvements in dystonia that were observed during the short-term infusions have been maintained during long-term therapy in six of eight children. The mean overall dystonia scores of the eight patients decreased from 25 prior to pump implantation to 14.6 12 months afterward (p Ͻ 0.05).
Discussion
We have described the use of continuous short-term infusion of intrathecal baclofen in persons with generalized dystonia associated with CP and the high response rates to such infusions. Hyperkinetic movement disorders become evident during childhood as the nervous system pathways mature. Although CP is a static encephalopathy, new motor abnormalities such as dystonia may appear during the first two decades after perinatal or early childhood asphyxia. 8, 15, 16, 20 Such dystonia may begin in an extremity and progress over several years to become generalized. The pharmacological treatment of dystonia in patients with CP has had limited success. There are few reports on the use of oral baclofen to treat dystonia associated with CP. Oral baclofen was given in dosages of 40 to 120 g/day to 16 children with idiopathic dystonia.
14 Seven children improved, five dramatically so, with an average dosage of 79 g/day. However, all patients were receiving other oral medications, such as trihexyphenidyl * Possible scores for each area ranged from 0 (best) to 4 (worst); potential overall scores, a total of the area scores, ranged from 0 to 32. Overall scores were significantly lower after infusion of intrathecal baclofen (p = 0.003, blinded rater and p = 0.0002, nonblinded rater). With the exception of the eyes, all area scores were also significantly (p Ͻ 0.05) lower after treatment. Blinded rater = observer blinded to treatment status; nonblinded rater = observer not blinded to treatment status.
hydrochloride, in addition to the baclofen. Patients improved gradually over weeks and were treated for a mean of 3.8 years, with sustained improvement.
Narayan and coworkers 17 were the first to treat dystonia with a continuous infusion of intrathecal baclofen. They described improvement of axial dystonia in an 18-year-old patient who received 825 g/day, with no adverse effects. Penn and colleagues 19 treated five adults with dystonia, primarily focal dystonia, with intrathecal baclofen and observed mixed results. Their patients' responses to baclofen were screened by bolus injections, after which pumps were implanted and the patients were given 300 to 960 g/day of baclofen. We recently reported positive responses to intrathecal baclofen in three patients with dystonic CP, but observed negative responses in two children with dystonia associated with Hallervordan-Spatz disease. 3 For the past 7 years, we have evaluated continuous intrathecal baclofen infusion in patients with spasticity of cerebral origin, primarily that associated with CP.
2,4,5
Intrathecal baclofen appears to improve spasticity by acting at the spinal cord level, inhibiting the release of excitatory neurotransmitters from afferent nerve endings in the superficial layers of the spinal cord. Baclofen inhibits the uptake of calcium that is required for glutamate release. 10, 18, 23 Within 2 hours after infusion of a single intrathecal baclofen dose of 50 to 100 g, lower-extremity spasticity is reduced and remains so for 6 to 8 hours. In previous studies of patients with mixed spastic-dystonic CP, single intrathecal baclofen doses (50-100 g) have reduced the spasticity, but have had no effect on the dystonia.
After initiation of continuous intrathecal baclofen infusion by means of either an external or implanted pump, dystonia generally does not improve for 2 or 3 days, a sufficient time for baclofen to enter the intracranial subarachnoid space. Because dystonia is not affected by single intrathecal baclofen boluses but is reduced by continuous infusion, we infer that baclofen's site of action in dystonia may be intracranial. In the model of basal ganglia function developed by DeLong, et al., 11 and Alexander and coworkers, 6 motor output is modulated by the corticobasal gangliothalamocortical circuit, which contains a direct and an indirect pathway. Lesions in the direct pathway typically result in hypokinetic movement disorders such as parkinsonism. Lesions in the indirect pathway, which includes the subthalamic nucleus, result in hyperkinetic movement disorders. Patients with secondary dystonia associated with CP often have lesions in the striatum, primarily in the putamen. The putamen normally inhibits the external globus pallidus, which inhibits the subthalamic nucleus. If the putamen were damaged by a perinatal insult, the deficient inhibition of the external globus pallidus (disinhibition) would result in excessive output from the subthalamic nucleus and, ultimately, in excessive stimulation of the premotor and supplementary motor cortices, causing hyperkinetic movements such as dystonia. Continuous infusion of intrathecal baclofen might improve dystonia by inhibiting the excessively stimulated supplementary motor cortex and premotor cortex.
Assessing dystonia is difficult, especially in persons with CP, because they may also have weakness, spasticity, lack of motor control, difficulty in communication, or cognitive deficits. We modified the Fahn-Marsden scale, a dystonia scale that rates patients according to provoking factors and severity factors. 1 In CP, however, there is often no provoking factor: dystonia is present both at rest and with volitional movement. Determining whether a movement is volitional is also challenging in patients with cognitive impairments. On the Fahn-Marsden scale, the severity factors are primarily based on function. Because most of the patients in our study were unable to perform functional tasks, we expanded the severity factors to include the severity of involuntary movements and posturing of the trunk and extremities. We believe the revised scale is a more appropriate measure for our patients.
The quantified improvements in dystonia during continuous infusion of intrathecal baclofen were accompanied by qualitative improvements in several patients: general level of comfort, sleeping, and ease of positioning in wheelchairs commonly improved. We did not evaluate function before and after intrathecal baclofen infusion because only two patients were capable of self-care.
Intrathecal baclofen infusions are associated with risks from the screening trial, pump implantation, and longterm therapy. The primary risk of the screening trial and pump implantation is meningitis or infection. Meningitis occurred in 4% of 51 patients in a multicenter study of continuous intrathecal baclofen infusion to treat cerebral spasticity (data on file, Medtronic, Inc.). During long-term therapy, overdoses may occur but are rare. They are almost always associated with either inaccurate programming of the pump or infusion of a bolus dose.
The results of this pilot study indicate that continuous infusion of intrathecal baclofen reduces generalized dystonia in some patients with CP. Thus far we cannot identify factors that might predict the response of dystonia to intrathecal baclofen. Additional investigations are being conducted to evaluate long-term responses and functional and quality-of-life outcomes.
